

## Suboxone - (2/0.5,4/1,8/2,12/3 mg; Film, Buccal, Sublingual)

<b>Generic Name</b>	Buprenorphine Hydrochloride and Naloxone Hydrochloride	<b>Innovator</b>	INDIVIOR INC
<b>Dosage</b>	2/0.5,4/1,8/2,12/3 mg; Film, Buccal, Sublingual	<b>Branded US Sales</b>	More Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	Indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.